Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4487 - A new chemotherapy-based combination to prevent osteosarcoma progression


11 Sep 2017


Poster display session


Translational Research;  Bone Sarcomas


Morgane Monchanin


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


M. Monchanin1, P. Berchard2, M. Vienne1, J.B. Langlois3, N. Gadot4, A. Bernet5, J. Blay6, A. Dutour7

Author affiliations

  • 1 Equipe C. Caux Et J.y Blay, CRCL, 69373 - Lyon Cedex/FR
  • 2 Equipe C. Caux Et J.y Blay, CRCL, 69373 - Lyon Cedex /FR
  • 3 In Vivo Imaging, CERMEP, 69677 - BRON/FR
  • 4 Anipath Platform, CRCL, 69373 - Lyon Cedex /FR
  • 5 Apoptosis And Cancer, CRCL, 69373 - Lyon Cedex /FR
  • 6 Département D'oncologie Médicale Adulte, Centre Léon Bérard, 69008 - Lyon/FR
  • 7 Crcl, Centre Léon Bérard, 69008 - Lyon/FR


Abstract 4487


Despite the intensification of chemotherapy regimen, 5 years survival rates for patients with metastatic or relapsed osteosarcoma (OS) remains of 20%. The secreted factor netrin 1 (Nt1) is overexpressed in many human cancers to block apoptosis. Recent studies showed that blocking Nt1 interaction with its receptors potentiates chemotherapy efficacy suggesting that combining chemotherapies with Nt1 interference could be a promising approach for chemoresistant tumors like OS.


Analyses of the ATGSarc database (http://atg-sarc.sarcomabcb.org/), indicate that Sarcoma with complex genomic (SCG) with a higher expression of Nt1 have a poorer outcome (p 


As pre operative treatment, Dox/aNt1 combination caused a marked delay in OS progression (median end point reached at day 17 and day 22 respectively in Dox and Dox/aNt1 group, (p  5mm) were found respectively in 75% and 17% of Dox and Dox/aNt1 treated rats As post operative treatment, Dox/aNt1combination significantly increased animals survival (median end point reached at day 15 and day 21 respectively in Dox and in Dox/aNt1 group; (p 


Our study reporting the antiproliferative and antimetastatic effects and of Dox/aNt1 Combination in OS indicate that this combined treatment could be a way to overcome OS chemoresistance.

Clinical trial identification

Legal entity responsible for the study

Dutour Aurélie




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.